Through in vivo and in vitro experiments, we found that miR-MTCO3P38 could suppress HCC progression by inhibiting the TMOD1/MMP13 pathway, providing a promising therapeutic target for the treatment of HCC. Here, MMP13 is linked to hepatocellular carcinoma.